β-glucose

Overview

β-Glucose refers to the β-anomeric form of glucose, a six-carbon monosaccharide and one of the principal simple sugars in biology. In aqueous solution, glucose exists in equilibrium between cyclic α- and β-anomeric forms, with the β form often predominating. As a central carbohydrate, glucose is fundamental to cellular energy metabolism, serving as a major substrate for glycolysis, oxidative phosphorylation, glycogen synthesis, and multiple biosynthetic pathways.

In biomedical research, β-glucose is usually discussed in the broader context of glucose biology rather than as a distinct therapeutic agent. It is clinically important as a circulating metabolite, a marker of glycemic status, and a substrate or trigger in assays, biosensors, and metabolic engineering systems. Its behavior is relevant to type 2 diabetes, diabetic ketoacidosis, chronic kidney disease, ischemic stroke, liver-related outcomes, and cancer metabolism, as well as to glucose-responsive biomaterials and Glucose oxidase (GOD)-based diagnostic platforms.

Recent Publications Summary

Recent publications have extensively studied β-glucose across multiple therapeutic and diagnostic contexts, with particular emphasis on continuous monitoring technologies and glucose-targeted interventions in diabetes management. Advanced biosensing platforms have been developed to enable real-time glucose detection in wearable formats, including enzymatic sensors based on glucose oxidase functionalization 42307818Jun, aptamer-based electrochemical biosensors for multiplex detection in cerebrospinal fluid 42127221May, time-gated fluorescent aptamer switches providing autofluorescence-free monitoring 42017428Apr, acoustic microneedle patches enabling enzyme-free continuous glucose monitoring over extended periods 42066084May, and integrated dual-microneedle systems combining continuous glucose monitoring with synchronized insulin delivery 42285381Jun. These technologies have demonstrated clinical relevance in point-of-care testing and wearable health monitoring applications.

In the therapeutic domain, β-glucose has emerged as a key target for treating bacteria-infected diabetic wounds through intelligent cascade nanoreactor systems. Zirconium-based metal-organic framework (Zr-MOF) nanozymes integrated with glucose oxidase have been shown to catalyze glucose consumption while simultaneously generating gluconic acid to neutralize alkaline wound pH and producing hydrogen peroxide to eliminate bacterial biofilms, with the resulting acidic microenvironment amplifying peroxidase-like activity 42584271Aug. Similarly, GOx@CuO2 nanoreactors exploit excess glucose at diabetic wound sites as a driving force for a self-perpetuating catalytic cascade that achieves glucose depletion, acid production, and generation of hydroxyl radicals for antibacterial effects, while intelligently switching to catalase-like activity to alleviate oxidative stress and promote angiogenesis 41759381Feb. Glucose-triggered self-reinforcing hydrogels based on carboxymethyl chitosan and oxidized hyaluronic acid have been engineered to absorb excess glucose from wound environments while delivering selenium nanoparticles with antibacterial and antioxidant properties 41832024Mar.

Glucose metabolism patterns have been identified as important diagnostic and prognostic markers across diverse clinical contexts. Postprandial glucose dynamics show substantial heterogeneity among individuals with obesity, with variations in curve peaks, dips, and overall response patterns uncorrelated with traditional area-under-the-curve measurements, suggesting that nuanced temporal analysis may reveal underlying physiological associations with disease risk 42166654May. In pediatric populations, β-glucose was identified as one of seven common differential metabolites in children with congenital hypothyroidism using NMR-based metabolomics, contributing to diagnostic models achieving 89.4% prediction accuracy 41973905Apr. Glucose levels have been evaluated as predictive factors in systemic lupus erythematosus-related infections 42557059Aug and as indicators of diabetic complications including fetal macrosomia risk in non-diabetic pregnant women 41800906Mar, highlighting its utility as a biomarker across multiple disease states.

Emerging pharmacological approaches have targeted glucose metabolism to enhance therapeutic efficacy in disease contexts beyond traditional diabetes management. silver nanoparticles biosynthesized from the fungus Porostereum spadiceum demonstrated enhanced antidiabetic activity in vitro through α-amylase and α-glucosidase inhibition, glucose adsorption assays, and yeast glucose uptake models, with in vivo studies in alloxan-induced diabetic mice confirming antidiabetic activity 42097278May. In hematologic malignancy, glucose dependency driven by active mammalian target of rapamycin signaling has been identified as a targetable metabolic vulnerability in chemotherapy-resistant B-cell acute lymphoblastic leukemia 41576347Jan. These findings collectively underscore β-glucose as both a critical monitoring parameter and a direct therapeutic target across multiple therapeutic strategies and disease contexts.

What Changes, What Holds

1. Wearable glucose sensors based on enzymatic and aptamer technologies enable continuous monitoring in clinical settings
METHOD Enzymatic, aptamer-based, and acoustic detection platforms shift glucose monitoring from traditional laboratory-based methods to real-time wearable formats. 42307818Jun42127221May Integrated dual-microneedle systems additionally enable synchronized insulin delivery. The Overview establishes glucose's role in biosensors; these findings represent new instrumental approaches to detecting and monitoring that established function without changing underlying biological understanding.

2. Glucose depletion in diabetic wounds through nanoreactor catalysis creates antimicrobial effects
NEW DIRECTION Zirconium nanozymes and copper oxide systems exploit excess wound glucose as fuel for self-sustaining reactions that simultaneously deplete glucose, acidify the environment, and generate antimicrobial species. 42584271Aug41759381Feb The Overview does not discuss therapeutic glucose consumption or glucose-driven catalytic cascades; glucose appears here as a substrate to be removed rather than monitored for energy.

3. Glucose temporal patterns and metabolite status predict disease progression across multiple conditions
REINFORCES Postprandial glucose dynamics correlate with obesity risk, glucose is a differential metabolite in congenital hypothyroidism, and glucose levels predict outcomes in lupus infections and pregnancy complications. 42166654May41973905Apr These findings extend glucose's established role as a metabolite marker to diverse disease contexts, confirming rather than revising the baseline's assertion of clinical importance.

4. Glucose dependency in leukemia represents a targetable metabolic vulnerability
NEW DIRECTION Glucose-dependent B-cell acute lymphoblastic leukemia driven by mTOR signaling identifies glucose metabolism as a novel therapeutic target in malignancy. 41576347Jan silver nanoparticles demonstrate additional antidiabetic activity through glucose metabolism inhibition. The Overview mentions glucose's relevance to cancer metabolism; this finding reframes glucose dependency as a direct therapeutic vulnerability distinct from its established role as an energy substrate.

Overview update candidates: Glucose depletion in diabetic wounds as a therapeutic strategy (entry 2); glucose dependency as a targetable metabolic vulnerability in hematologic malignancy (entry 4).